<DOC>
	<DOC>NCT00144339</DOC>
	<brief_summary>The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.</brief_summary>
	<brief_title>Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Written informed consent. Male or female patients 40 years of age or older. Smoking history of at least 10 pack years. Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1&lt;70% of FVC and on stable respiratory medication. Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate. Myocardial infarction in past 6 months. Unstable or life threatening arrhythmia in past year. Hospitalization for NYHA heart failure class III or IV in past year. Active tuberculosis. Asthma. Pulmonary resection. Malignancy treated with radiation or chemotherapy in past 5 years. Respiratory infection in 4 weeks prior to screening. Known hypersensitivity to anticholinergic drugs or components. Known moderate to severe renal impairment. Known narrow angle glaucoma. Significant symptomatic BPH or bladder neck obstruction. Need for oxygen therapy &gt;12 hr/day. Use of oral corticosteroids at unstable doses or &gt;10 mg/day.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>